Very low intensity ultrasounds as a new strategy to improve selective delivery of nanoparticles-complexes in cancer cells

Abstract

BackgroundThe possibility to combine Low Intensity UltraSound (LIUS) and Nanoparticles (NP) could represent a promising strategy for drugs delivery in tumors difficult to treat overcoming resistance to therapies. On one side the NP can carry drugs that specifically target the tumors on the other the LIUS can facilitate and direct the delivery to the tumor cells. In this study, we investigated whether Very Low Intensity UltraSound (VLIUS), at intensities lower than 120 mW/cm2, might constitute a novel strategy to improve delivery to tumor cells. Thus, in order to verify the efficacy of this novel modality in terms of increase selective uptake in tumoral cells and translate speedily in clinical practice, we investigated VLIUS in three different in vitro experimental tumor models and normal cells adopting three different therapeutic strategies.MethodsVLIUS at different intensities and exposure time were applied to tumor and normal cells to evaluate the efficiency in uptake of labeled human ferritin (HFt)-based NP, the delivery of NP complexed Firefly luciferase reported gene (lipoplex-LUC), and the tumor-killing of chemotherapeutic agent.ResultsSpecifically, we found that specific VLIUS intensity (120 mW/cm2) increases tumor cell uptake of HFt-based NPs at specific concentration (0.5 mg/ml). Similarly, VLIUS treatments increase significantly tumor cells delivery of lipoplex-LUC cargos. Furthermore, of interest, VLIUS increases tumor killing of chemotherapy drug trabectedin in a time dependent fashion. Noteworthy, VLIUS treatments are well tolerated in normal cells with not significant effects on cell survival, NPs delivery and drug-induced toxicity, suggesting a tumor specific fashion.ConclusionsOur data shed novel lights on the potential application of VLIUS for the design and development of novel therapeutic strategies aiming to efficiently deliver NP loaded cargos or anticancer drugs into more aggressive and unresponsive tumors niche.Electronic supplementary materialThe online version of this article (10.1186/s13046-018-1018-6) contains supplementary material, which is available to authorized users.

Potential roles and prognostic significance of exosomes in cancer drug resistance

“…Cesi et al showed that a novel truncated form of ALK can be shuttled by vemurafenib resistant melanoma cell-derived exosomes and promote resistance phenotype in recipient cells [ 77 ]. Moreover, exosome-mediated transfer of p-STAT3 from resistant cells significantly promoted cell survival and 5-FU resistance both in vitro and in vivo [ 78 ].…”

Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis

“…Another study showed that adipocytes induced CD36 expression in ovarian cancer cells, which promoted metastasis of cancer cells in peritoneum and omentum [ 147 ]. And also, CD36 was shown to be a key mediator of fatty acids-induced metastasis of gastric cancer cells via the AKT/glycogen synthase kinase (GSK)-3β/β-catenin signaling pathway [ 148 ].…”

Microrheology for biomaterial design

“… 111 Models of the tumor immune microenvironment have also been developed to better understand cancer-immune interactions, in order to enhance immunotherapy efficacy. 112 The biophysical properties of these complex models have been effectively characterized using microrheology.…”